GW Pharmaceuticals (NASDAQ: GWPH) announced this morning that the European Commission has approved the marketing authorization for the company's plant-derived CBD-based epilepsy drug Epidyolex. Epidyolex was created to treat seizures... read more →
The FDA is Set to Re-Open Public Comments to Seek Input on the Rescheduling of Cannabis This Could Be the First of Many Major Catalysts That Will Drive These U.S.... read more →
- Epidiolex U.S. Q1 net sales of $33.5m - - Positive Phase 3 pivotal results in Tuberous Sclerosis Complex, sNDA submission expected in Q4 2019 - - Conference call today... read more →
CBD remains the talk of main street. The non-psychoactive component in Cannabis, and often referred to as the ‘sibling’ of THC, is claimed to have a myriad of health benefits... read more →
Canopy Growth Adds Martha Stewart as Advisor, Will Assist on New Hemp CBD Products: Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) and Sequential Brands Group, Inc. (NASDAQ: SQBG) announced today that Martha Stewart... read more →
Epidiolex® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine, launched in the U.S. in November to high awareness and demand GW moves to a new fiscal year-end beginning January 1,... read more →